Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693
This study is a first time in human, Phase I, open-label study to determine recommended doses and schedules, based on maximum tolerated doses and biologically active doses, for the AKT inhibitor GSK690693.
Cancer
DRUG: GSK690693
To determine the maximum tolerated dose of GSK690693 given weekly or twice weekly over 1 - 4 hours., given weekly or twice weekly over 1 - 4 hours
Blood pressure and heart rate every 8 hours., every 8 hours.|12-lead ECGs will be conducted at 4, 8, 10, 12, 14, 24hrs, 4, 8, 10, 12, 14, 24hrs|Pharmacokinetics and Pharmacodynamics via blood draws before, during, and after the infusion., draws before, during, and after the infusion|Urinalysis samples while the patient is hospitalized, while the patient is hospitalized
This study is a first time in human, Phase I, open-label study to determine recommended doses and schedules, based on maximum tolerated doses and biologically active doses, for the AKT inhibitor GSK690693.